Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-IRDye 800CW for pancreatic cancer imaging
NCT02736578Phase 2Terminated
- Sponsor
- Eben Rosenthal
- Start
- Jul 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab-IRDye 800CW in pancreatic adenocarcinoma (PDAC), sponsored by Eben Rosenthal. Primary endpoint: Peri-operative Cetuximab-IRDye800 Fluorescent Imaging up to 5 days. Started Jul 2016; status: terminated.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02736578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736578.